<DOC>
	<DOCNO>NCT00672243</DOCNO>
	<brief_summary>Primary objective : To determine 6-month progression free survival patient recurrent glioblastoma multiforme ( GBM ) treat Erlotinib plus Sirolimus . Secondary objective : To define safety tolerability Erlotinib plus Sirolimus administer patient recurrent GBM ; evaluate progression free survival , radiographic response overall survival patient recurrent GBM treat Erlotinib plus Sirolimus .</brief_summary>
	<brief_title>Ph II Erlotinib + Sirolimus Pts w Recurrent Malignant Glioma Multiforme</brief_title>
	<detailed_description>The primary objective study determine 6-month progression free survival patient recurrent GBM treat Erlotinib plus Sirolimus . This exploratory , single-arm , phase II study design assess anti-tumor activity combinatorial regimen consist Erlotinib plus Sirolimus among patient recurrent GBM . The combinatorial regimen Erlotinib plus Sirolimus rationally design simultaneously inhibit upstream ( EGFR ) downstream ( mTOR ) mediator Phosphatidylinositide 3-kinase/Protein Kinase B ( PI3/AKT ) signal . In recently complete phase I study , determine EGFR inhibitor ( Gefitinib ) safely combine Sirolimus dose level routinely use monotherapy setting . Therefore , primary endpoint study probability progression-free survival 6 month among recurrent GBM patient treat standard dos Erlotinib plus Sirolimus . An important secondary objective ass safety Erlotinib Sirolimus patient recurrent GBM .</detailed_description>
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Glioma</mesh_term>
	<mesh_term>Gliosarcoma</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>Pts confirm diagnosis recurrent primary WHO grade IV malignant glioma ( MG ) . Pts w recurrent disease whose diagnostic pathology confirm GBM need rebiopsy . Pts w prior lowgr glioma / anaplastic glioma eligible histologic assessment demonstrate transformation GBM Age &gt; 18 yr Interval &gt; 2 wk prior surgical resection Interval &gt; 12 wks prior externalbeam radiation therapy ( XRT ) unless either : histopathologic confirmation recurrent tumor ; new enhancement MRI outside XRT treatment field ; / progressive radiographic change XRT/temo well adjuvant , postXRT temo Interval &gt; 4 wks chemo &amp; enrollment protocol unless : unequivocal evidence tumor progression ; &amp; pt recover fully toxicity associate w prior surgery , XRT/chemo . Pts treat w chemo agent VP16 would normally retreat short interval may treat usual starting time even &lt; 4 wks last prior dose chemo Karnofsky performance score &gt; = 70 percent Hematocrit &gt; 29 percent , absolute neutrophil count ( ANC ) &gt; 1,500 cells/microliter , platelet &gt; 100,000 cells/microliter Serum creatinine &lt; 1.5 mg/dl , serum glutamic oxaloacetic transaminase ( SGOT ) &amp; bilirubin &lt; 1.5 x upper limit normal ( ULN ) ; fast plasma triglyceride &amp; cholesterol &lt; gr1 For pt corticosteroid , dose increase &gt; 7 day prior baseline GdMRI brain medically appropriate Pts enzyme induce antiepileptic drug cohort must stable dose p450inducing EIAED &gt; 2 wks . Pts nonEIAED cohort must receive p450EIAED &gt; 2 wks prior &amp; participation trial Signed informed consent approve Institutional Review Board ( IRB ) prior pt entry If sexually active , pt take contraceptive measure duration treatment &amp; 3 month follow discontinuation Erlotinib Pts prior bevacizumab eligible however interval &gt; 6 week must elapse since last dose Prior mammalian target rapamycin ( mTOR ) direct therapy Prior epidermal growth factor receptor ( EGFR ) direct therapy Female pt pregnant/breast feeding , adult reproductive potential employ effective method birth control . Women childbearing potential must negative serum pregnancy test &lt; 72 hour prior administration Erlotinib Comedication may interfere w study result Uncontrolled intercurrent illness include , limited , ongoing active infection require IV antibiotic , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , hyperlipidemia control w medication , psychiatric illness/social situation would limit compliance w study requirement , /disorders associate w significant immunocompromise Acute/chronic liver disease Impairment GI function/GI disease may significantly alter absorption Erlotinib Pts receive investigational drug &lt; 4 wks prior entry study recover toxic effect therapy Pts receive biologic , immunotherapeutic/cytostatic agent &lt; 1 wk prior entry study/have recover toxic effect therapy Pt &lt; 5 yr free another primary malignancy except : primary malignancy currently clinically significant/requiring active intervention , /if primary malignancy basal cell skin cancer/cervical carcinoma situ . Existence malignant disease allow Pts surgery resection brain tumor &lt; 2 wks prior entry study/have recover side effect therapy Pts unwilling to/unable comply w protocol Pts w acute/chronic renal insufficiency/those w acute renal insufficiency severity due hepatorenal syndrome/in perioperative liver transplantation period</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>GBM</keyword>
	<keyword>Brain tumor</keyword>
	<keyword>Erlotinib</keyword>
	<keyword>Sirolimus</keyword>
	<keyword>Glioblastoma multiforme</keyword>
	<keyword>Glioblastoma</keyword>
	<keyword>Gliosarcoma3</keyword>
	<keyword>Tarceva</keyword>
	<keyword>Rapamune</keyword>
</DOC>